Special Issue

The Discovery of Novel beta-Lactams and beta-Lactamase Inhibitors

Message from the Guest Editors

Antibiotic resistance poses a significant global threat as bacteria continue to evolve to evade these life-saving drugs. One major challenge is the widespread production of beta-lactamases, which are enzymes capable of hydrolyzing the beta-lactam bond, rendering the drugs inactive. To combat this, researchers are actively exploring novel beta-lactam antibiotics and beta-lactamase inhibitors. We are pleased to invite you to contribute an original research article or review to this Special Issue of Antibiotics titled “The Discovery of Novel beta-Lactams and beta-Lactamase Inhibitors”. This Special Issue aims to highlight important contributions in the field of antibiotic resistance. Research articles may cover topics such as novel beta-lactam antibiotic and/or beta-lactamase inhibitors; new methods of designing novel compounds; identification of new targets in antibiotic resistant bacteria; innovative compound library screening methods/techniques; and many more. Review articles on current topics related to antibiotic resistance, the discovery of new beta-lactams, and/or beta-lactamase inhibitors are also welcome. We look forward to receiving your contributions.

Guest Editors

Dr. Caitlyn Thomas

Department of Chemistry and Biochemistry, University of Notre Dame, 352 McCourtney Hall, Notre Dame, IN 46556, USA

Prof. Dr. Juhee Ahn

Department of Medical Biomaterials Engineering, Kangwon National University, Chuncheon 24341, Gangwon, Republic of Korea

Deadline for manuscript submissions

15 January 2026

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/234997

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI